Tempur-Pedic (TPX) Tops Q4 EPS by 2c, Sales Top Slightly; Offers Strong FY12 Outlook
Tweet
Share
E-mailGet Alerts TPX Hot Sheet
Price: $68.78 --0%
Financial Fact:
Other expense, net: 300K
Today's EPS Names:
VAXX, NMRD, EGRX, More
Financial Fact:
Other expense, net: 300K
Today's EPS Names:
VAXX, NMRD, EGRX, More
Join SI Premium – FREE
Tempur-Pedic International, Inc. (NYSE: TPX) reported Q4 EPS of $0.84, $0.02 better than the analyst estimate of $0.82. Revenue for the quarter came in at $366.8 million versus the consensus estimate of $364.36 million.
Sees FY12 EPS of $3.80-$3.95 on sales of $1.6-$1.65 billion. The Street is currently expecting FY12 EPS of $3.77 on sales of $1.59 billion.
For earnings history and earnings-related data on Tempur-Pedic International, Inc. (TPX) click here.
Sees FY12 EPS of $3.80-$3.95 on sales of $1.6-$1.65 billion. The Street is currently expecting FY12 EPS of $3.77 on sales of $1.59 billion.
For earnings history and earnings-related data on Tempur-Pedic International, Inc. (TPX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
- Pelthos Therapeutics Inc. (PTHS) Misses Q2 EPS by 611c
- McGraw Hill (MH) Tops Q2 EPS by 11c, Beats on Revenue; Offers FY26 Guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
